NASH with Fibrosis Study


18 - 65


Columbus, OH


Up to $2,988*

NASH with Fibrosis Trials in Columbus

Aventiv Research is currently participating in a phase 1, NASH with fibrosis study at our Columbus, Ohio location. Non-alcoholic steatohepatitis (NASH) is a condition in which build-up of fat in the liver causes inflammation and damage in the liver. Progression of NASH leads to abnormal liver function which results in conditions like liver disease (cirrhosis), liver failure, and liver cancer.

NASH is linked to obesity, insulin resistance, high blood sugar, and high levels of fats in the blood. While some people experience fatigue or pain or swelling in the abdomen, most people do not display any symptoms, making NASH difficult to diagnose. Advances in drug therapy are key to treating this disease at its early stages and preventing further liver damage.

Enroll Now

NASH with Fibrosis Study

The primary objective of this clinical study is to assess safety and tolerability of an investigational drug in participants with NASH who have the PNPLA3 gene variant. You may be eligible to participate if you:

  • Are 18 to 65 years of age
  • Have had a previous qualifying liver biopsy or
    • Consent to a liver biopsy at screening
  • Have the PNPLA3 gene variant
  • Have a body weight ≥50 kg and BMI within the range 25 to 45 kg/m2

This clinical trial requires multiple overnight stays at our study site during the dosing period.

We now offer individuals with known risk factors of Non-Alcoholic Fatty Liver Disease (NAFLD) a free Fibroscan screening.

Ready to Volunteer?

Volunteer today to see if you qualify for our NASH with Fibrosis clinical research study. *Qualified volunteers may be compensated for time and travel.